Start with education—not a treatment menu.
This educational guide does not diagnose, prescribe, recommend a peptide, provide a dose, or authorize self-injection. Many compounds promoted online as “peptides” are not FDA-approved for human use, and compounded drugs are not reviewed by FDA for safety, effectiveness, or quality before marketing. Personal decisions belong with a licensed clinician using a legal, traceable product.
The takeaway Personal decisions belong with a licensed clinician using a legal, traceable product.
One word. Four very different categories.
Peptides are short chains of amino acids. Some are established prescription medicines with narrowly defined indications. Others are experimental compounds with limited human data. Still others are food-derived collagen fragments or cosmetic ingredients. Their risks, evidence, and legal status are not interchangeable.
Approved medicine
Reviewed by FDA for a named condition, formulation, dose, manufacturing process, and label. Approval for one indication does not prove every marketed use.
Compounded preparation
May serve a patient-specific need, but it is not FDA-approved. Quality and legal eligibility depend on the substance, pharmacy, prescription, and federal and state rules.
Research peptide
May have laboratory, animal, or early human data without an approved consumer product. “Research use only” does not make self-treatment safe or lawful.
Nutrition or cosmetic peptide
Products such as collagen hydrolysates or topical cosmetic peptides are different from injectable drugs and should not inherit claims made for prescription medicines.
The takeaway “Peptide” describes a molecule—not a safety rating.
Know what the name actually refers to.
The profiles distinguish regulatory status, evidence, and safety. A product’s inclusion here does not mean it is offered by OptimalMD or that it will become available.
Education only. Not an OptimalMD product menu. Additional peptide offerings are not yet available through OptimalMD.
Showing all 18 profiles
Choose a name to open its complete profile, evidence, cautions, and source link.
01SemaglutideGLP-1 receptor agonistFDA-approved examples
FDA-approved semaglutide products exist for specific chronic weight-management and type 2 diabetes indications. Product label, indication, formulation, and prescriber guidance matter.
What to know
It is a peptide-based prescription medicine—not a general proof that all peptides are safe. Use only the exact prescribed product and instructions. Do not copy a schedule from a different formulation.
FDA prescribing information ↗02TesamorelinGHRH analogFDA-approved—narrow use
EGRIFTA SV is approved to reduce excess abdominal fat in adults with HIV and lipodystrophy. It is not approved as general weight-loss therapy.
What to know
The label includes contraindications, glucose and IGF-1 monitoring, and product-specific mixing, storage, and administration instructions. Athletes should also check anti-doping rules.
FDA label and instructions ↗03Bremelanotide (PT-141)Melanocortin receptor agonistFDA-approved—narrow use
Vyleesi is approved for acquired, generalized hypoactive sexual desire disorder in certain premenopausal women. It is not approved for men or to enhance sexual performance.
What to know
The FDA label warns about transient blood-pressure increases, nausea, and focal hyperpigmentation and defines who should not use it.
FDA prescribing information ↗04BPC-157Experimental synthetic peptideNot FDA-approved
Widely marketed for tendon, ligament, muscle, wound, and gastrointestinal recovery. Much of the cited evidence is preclinical; there is no FDA-approved BPC-157 drug for these uses.
Evidence & caution
FDA identifies limited safety information, possible immunogenicity, peptide-impurity concerns, and insufficient information to know whether proposed routes could harm humans.
FDA compounding safety review ↗05TB-500Thymosin-beta-4–related fragmentInvestigational
Marketed for wound and soft-tissue recovery, but it does not have an FDA-approved consumer indication. Human effectiveness and long-term safety remain uncertain.
Evidence & caution
TB-500 is included in current FDA compounding review activity and is prohibited in sport under WADA’s growth-factor provisions.
FDA 2026 committee material ↗06CJC-1295Experimental GHRH analogNot FDA-approved
Promoted for growth-hormone release, recovery, body composition, and sleep—often with ipamorelin. Those marketed outcomes are not approved indications.
Evidence & caution
FDA reports limited clinical data, immunogenicity and impurity concerns, and serious adverse events including increased heart rate and a systemic vasodilatory reaction.
FDA compounding safety review ↗07IpamorelinGrowth-hormone secretagogueNot FDA-approved
Commonly paired with CJC-1295 and marketed for recovery, muscle, sleep, and body composition. No FDA-approved ipamorelin product establishes those benefits or a consumer cycle.
Evidence & caution
FDA cites peptide-characterization and immunogenicity concerns, serious adverse events in an intravenous study, and insufficient information about harm through other injection routes.
FDA compounding safety review ↗08AOD-9604Modified growth-hormone fragmentNot FDA-approved
Marketed for fat loss and metabolism. It has no FDA-approved weight-loss indication and no validated do-it-yourself protocol.
Evidence & caution
FDA identifies limited safety information, immunogenicity and impurity concerns, and serious adverse events with unclear causality. WADA prohibits growth-hormone fragments.
FDA compounding safety review ↗09GHK-CuCopper-binding peptideInjection not FDA-approved
Seen in skin and hair products and also marketed by some clinics as an injection. Topical cosmetic use and injectable drug use are different categories.
Evidence & caution
FDA says compounded injectable GHK-Cu may present immunogenicity and peptide-impurity risks and that human safety data are limited. A cosmetic label does not establish injectable safety.
FDA compounding safety review ↗10MOTS-cMitochondrial-derived peptideInvestigational
Marketed for metabolism, exercise capacity, body composition, and longevity. There is no FDA-approved MOTS-c product for these goals.
Evidence & caution
FDA says it found no human-exposure data for drug products containing MOTS-c and lacks information needed to know whether it could harm humans.
FDA compounding safety review ↗11SemaxSynthetic ACTH-fragment analogNot FDA-approved in U.S.
Promoted online for focus, cognition, mood, and neurologic recovery. These are not FDA-approved U.S. indications.
Evidence & caution
FDA flags potential immunogenicity and peptide-related impurities and says important human safety information is lacking. Semax remained under federal compounding review in 2026.
FDA 2026 committee material ↗12SelankExperimental synthetic peptideNot FDA-approved in U.S.
Promoted for anxiety, mood, and cognitive support. There is no FDA-approved U.S. drug establishing those uses, quality, or consumer instructions.
Evidence & caution
FDA identifies possible immunogenicity and impurity risks and says it lacks important safety information about administration to humans.
FDA compounding safety review ↗13Kisspeptin-10Reproductive-axis signaling peptideInvestigational
Studied in reproductive endocrinology and marketed for fertility, libido, or testosterone support. There is no broad FDA-approved wellness indication.
Evidence & caution
FDA lists immunogenicity and peptide-characterization concerns for certain compounded routes. Kisspeptin and agonist analogs are prohibited in male athletes under WADA rules.
FDA compounding safety review ↗14IGF-1 LR3Long-acting IGF-1 analogNot FDA-approved
Promoted for muscle growth and performance. It is distinct from FDA-approved mecasermin and has no approved bodybuilding or wellness use.
Evidence & caution
Online protocols should not be treated as clinical evidence. IGF-1 and its analogs are prohibited in sport, and a related approved drug does not validate an unapproved analog.
WADA 2026 Prohibited List ↗15Follistatin 344Myostatin-pathway research compoundExperimental
Promoted for muscle growth by influencing activin/myostatin signaling. There is no FDA-approved follistatin-344 consumer drug or established wellness cycle.
Evidence & caution
Claims often extrapolate from pathway science rather than validated clinical outcomes. Myostatin and activin signaling manipulation is also relevant to anti-doping controls.
WADA scientific program ↗16Collagen peptidesHydrolyzed dietary proteinNutrition category
Powdered collagen peptides are food-derived protein fragments—not injectable signaling drugs. Product quality, protein intake, allergies, and realistic expectations still matter.
What to know
Do not transfer claims between dietary collagen, topical peptides, and injected research compounds. They differ in route, regulation, exposure, and evidence.
FDA supplement overview ↗17Topical cosmetic peptidesExamples: Matrixyl-type ingredientsCosmetic category
Used in skin-care formulas with claims related to appearance, hydration, or firmness. A cosmetic is not reviewed like an approved prescription drug and cannot prove injectable safety.
What to know
Check the full ingredient list, patch-test when appropriate, stop for irritation, and involve a dermatologist for persistent skin problems.
FDA cosmetics framework ↗18MK-677 (Ibutamoren)Small-molecule ghrelin agonistNot actually a peptide
Often grouped with peptide stacks because it can stimulate growth-hormone signaling, but it is not a peptide and is not FDA-approved for bodybuilding, recovery, or anti-aging.
Why the distinction matters
Calling every growth-hormone–related compound a peptide hides meaningful differences in chemistry, evidence, side effects, and regulation. Ibutamoren is also prohibited in sport.
WADA 2026 Prohibited List ↗No matching profile
Try a different compound name, goal, or status filter.
The takeaway Risks, evidence, and legal status are not interchangeable. Read the profile for the exact product.
An online “cycle” is not a care plan.
Fitness and wellness sites use “cycle” to describe a self-selected period of use, sometimes combined with other compounds. That is not the same as an FDA-approved dosing schedule or a clinician’s prescription.
Do not treat online cycles as instructions
- There is no universal cycle shared by all peptides.
- An animal study, forum post, or clinic blog is not a dosing authority.
- Stacking compounds makes cause, interaction, and adverse-effect tracking harder.
- “No PCT required,” “safe long term,” and “side-effect free” are not reliable safety guarantees.
- Research-use labeling is not permission for human self-administration.
Use the care plan that actually applies
- Approved drug: follow the current label and personal prescriber instructions.
- Clinical trial: follow the registered protocol and research team.
- Compounded drug: verify why an approved option cannot meet the patient-specific need, then follow the licensed prescriber and dispensing pharmacy.
- Research peptide: do not create a consumer cycle from online content.
The takeaway There is no universal cycle shared by all peptides.
Think before, during, and after care.
These are conversation and safety checkpoints. Exact storage, preparation, administration, monitoring, and missed-dose instructions must come from the product label, prescriber, and dispensing pharmacy.
Verify the product and purpose
- Exact generic and brand name
- FDA status and approved indication
- Why it is appropriate for you
- Medication, allergy, pregnancy, and condition review
- Licensed prescriber and traceable pharmacy
Receive product-specific training
- Correct formulation and concentration
- Storage and travel instructions
- Preparation only if the label requires it
- Injection demonstration if prescribed
- Sharps container and disposal plan
Track response and safety
- Expected effects and realistic timeline
- Side effects and symptom pattern
- Relevant vitals and laboratory monitoring
- Interactions and upcoming procedures
- When to call, pause, or seek urgent care
Change only with the care team
- No dose or schedule changes alone
- No cross-product measurement assumptions
- No sharing needles, syringes, or medicine
- Review whether benefit still outweighs risk
- Use a safe stop or transition plan
The takeaway Exact instructions must come from the product label, prescriber, and dispensing pharmacy.
Bring questions. Know when to get help.
Ten questions worth asking
- Is this exact product FDA-approved? For what condition?
- If compounded, what patient-specific need requires it?
- What human evidence supports my intended use?
- What are the important contraindications and interactions?
- Which baseline labs, vitals, or exams are appropriate?
- What changes should I expect—and by when?
- Which side effects require a call or urgent care?
- How do I store, travel with, and dispose of supplies?
- How will we decide whether to continue or stop?
- Could this violate my sport, employment, or licensing rules?
Urgent safety boundary
Do not wait on dangerous symptoms
Call 911 or seek immediate medical care for trouble breathing; swelling of the face, lips, tongue, or throat; fainting; severe confusion; chest pain; signs of stroke; or another life-threatening reaction.
Contact the care team promptly for severe or persistent vomiting, dehydration, worsening abdominal pain, concerning injection-site changes, significant blood-pressure or blood-sugar changes, or any symptom named in the product’s medication guide.
This list is not complete. The exact product label controls.
The takeaway Keep the care team involved, and do not wait on dangerous symptoms.
Check the rules that apply to you.
The 2026 WADA Prohibited List includes growth-hormone–releasing factors and secretagogues such as CJC-1295, tesamorelin, ipamorelin, and ibutamoren; growth-hormone fragments such as AOD-9604; IGF-1 analogs; and thymosin-beta-4 derivatives such as TB-500. Check the current list and therapeutic-use exemption process before use.
Open the 2026 WADA list ↗The takeaway Prescription does not automatically mean permitted in sport.